Anti-fgfr2 Monoclonal Antibody Fpa144
Anti-fgfr2 Monoclonal Antibody Fpa144 Uses, Dosage, Side Effects, Food Interaction and all others data.
Anti-fgfr2 Monoclonal Antibody Fpa144 is under investigation in clinical trial NCT03694522 (A Study of Anti-fgfr2 Monoclonal Antibody Fpa144 (FPA144) Combined With Modified FOLFOX6 (Mfolfox6) in Gastric/gastroesophageal Junction Cancer (FIGHT)).
| Trade Name | Anti-fgfr2 Monoclonal Antibody Fpa144 |
| Generic | Bemarituzumab |
| Bemarituzumab Other Names | Anti-fgfr2 monoclonal antibody fpa144, Bemarituzumab |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Innovators Monograph
You find simplified version here Anti-fgfr2 Monoclonal Antibody Fpa144
